Results 11 to 20 of about 244 (83)

Acetylation Stabilizes Phosphoglycerate Dehydrogenase by Disrupting the Interaction of E3 Ligase RNF5 to Promote Breast Tumorigenesis

Cell Reports, 2020
Summary: Phosphoglycerate dehydrogenase (PHGDH) is the first enzyme in the serine synthesis pathway in which it is also the rate-limiting enzyme. It is significantly upregulated in many cancers, especially breast cancer.
Chao Wang, Xingyou Wan, Tong Yu, Zhenyu Huang, Chao Shen, Qian Qi, Sheng Xiang, Xinyuan Chen, Eyal Arbely, Zhi-Qiang Ling, Chen-Ying Liu, Wei Yu   +11 more
doaj   +1 more source

PHGDH supports liver ceramide synthesis and sustains lipid homeostasis

Cancer & Metabolism, 2020
Background d-3-phosphoglycerate dehydrogenase (PHGDH), which encodes the first enzyme in serine biosynthesis, is overexpressed in human cancers and has been proposed as a drug target.
Yun Pyo Kang, Aimee Falzone, Min Liu, Paloma González-Sánchez, Bo-Hyun Choi, Jonathan L. Coloff, James J. Saller, Florian A. Karreth, Gina M. DeNicola   +8 more
doaj   +1 more source

Targeting phosphoglycerate dehydrogenase in multiple myeloma

Experimental Hematology & Oncology, 2021
Background Multiple myeloma (MM) is a hematological malignancy characterized by the clonal expansion of plasma cells in the bone marrow. To date, this disease is still incurable and novel therapeutic approaches are required.
Samah Elsaadi, Ida Steiro, Pegah Abdollahi, Esten N. Vandsemb, Rui Yang, Tobias S. Slørdahl, Torstein Baade Rø, Eline Menu, Anne-Marit Sponaas, Magne Børset   +9 more
doaj   +1 more source

PHGDH Is Upregulated at Translational Level and Implicated in Platin-Resistant in Ovarian Cancer Cells

Frontiers in Oncology, 2021
BackgroundPlatinum-based chemotherapy is the first line option for ovarian cancer. The development of resistance to such chemotherapy results in treatment failure, while the underlying mechanisms are poorly understood.MethodsClinical samples were ...
Fangfang Bi, Yuanyuan An, Tianshui Sun, Yue You, Qing Yang   +4 more
doaj   +1 more source

Increased PHGDH expression promotes aberrant melanin accumulation

BMC Cancer, 2019
Background Copy number gain of the D-3-phosphoglycerate dehydrogenase (PHGDH) gene, which encodes the first enzyme in serine biosynthesis, is found in some human cancers including a subset of melanomas.
Katherine R. Mattaini, Mark R. Sullivan, Allison N. Lau, Brian P. Fiske, Roderick T. Bronson, Matthew G. Vander Heiden   +5 more
doaj   +1 more source

Can small molecular inhibitors that stop de novo serine synthesis be used in cancer treatment?

Cell Death Discovery, 2021
To sustain their malignancy, tumour cells acquire several metabolic adaptations such as increased oxygen, glucose, glutamine, and lipids uptake. Other metabolic processes are also enhanced as part of tumour metabolic reprogramming, for example, increased
Megan Jessica McNamee, David Michod, Maria Victoria Niklison-Chirou   +2 more
doaj   +1 more source

High Expression of PHGDH Predicts Poor Prognosis in Non–Small Cell Lung Cancer

Translational Oncology, 2016
Tumors have exceptionally high demands for energy and anabolism because of their rapid growth. The de novo serine synthesis pathway initiated by phosphoglycerate dehydrogenase (PHGDH) has been recognized as a hallmark of metabolic adaption in ...
Jinhong Zhu, Jianqun Ma, Xudong Wang, Tianjiao Ma, Shu Zhang, Wei Wang, Xiaoyu Zhou, Jiahai Shi   +7 more
doaj   +1 more source

The metabolic reprogramming and vulnerability of SF3B1 mutations

Molecular & Cellular Oncology, 2020
Mutations in the splicing factor 3b subunit 1 (SF3B1) gene create a neomorphic protein that disrupts RNA splicing, but the downstream consequences of this missplicing are unclear.
W. Brian Dalton
doaj   +1 more source

Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E

Journal of Experimental & Clinical Cancer Research, 2019
Background Pancreatic cancer is one of the most malignant cancers. The overall 5-year survival rate of its patients is 8%, the lowest among major cancer types.
Xuhui Ma, Boya Li, Jie Liu, Yan Fu, Yongzhang Luo   +4 more
doaj   +1 more source

Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma

Molecular & Cellular Oncology, 2021
The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer.
Richa Rathore, Brian Van Tine
doaj   +1 more source